RxDoctor Payments Data

Christina Weiss

Psychiatric/Mental Health · Paramus, NJNPI 1497130736

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 386 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,865 and has fallen 91.7% since, to $155 in 2025. Among psychiatric/mental health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,365in general payments, 2019–2025

Across 386 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$870
  • Teva Pharmaceuticals USA, Inc.$715
  • Neurocrine Biosciences, Inc.$695
  • Alkermes, Inc.$597
  • Otsuka America Pharmaceutical, Inc.$466
  • Supernus Pharmaceuticals, Inc.$428
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$6,19597%
  • Education$1703%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,365 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl41$111,920
RexultiBrexpiprazole11$26,204
OzempicSemaglutide16$14,924
DayvigoLemborexant11$3,635
Escitalopram Oxalate49$727
Bupropion XlBupropion Hcl20$705
Mirtazapine36$694
Olanzapine37$603
Clozapine11$527
Clonazepam55$477
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine20$387
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$370
Sertraline Hcl44$312
Quetiapine Fumarate16$253
Trazodone Hcl15$219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$150$111,92041 claims
Otsuka America Pharmaceutical, Inc.Rexulti$466$26,20411 claims
Novo NordiskOzempic$102$14,92416 claims
Almatica Pharma LLCSertraline Hcl$204$31244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →